Last reviewed · How we verify
NCT05675501
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
Phase 1 trial testing Encapsulated Benzoyl Peroxide Cream in Papulopustular Rosacea in 31 participants. Completed in 15 July 2021.
15 July 2021
Quick facts
| Lead sponsor | Sol-Gel Technologies, Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 31 |
| Start date | 10 June 2020 |
| Primary completion | 15 July 2021 |
| Estimated completion | 15 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Encapsulated Benzoyl Peroxide Cream — full drug profile →
Conditions studied
- Papulopustular Rosacea — all drugs for Papulopustular Rosacea →
Sponsor
Sol-Gel Technologies, Ltd. — full company profile →
Who can join
18 and older, any sex, with Papulopustular Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to assess how the use of the drug may shift the skin microbiome and skin biophysical properties. Specifically, the study objectives were to assess the following: * How the drug affects the skin microbiome compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea. * How the drug affects the skin physical properties compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05675501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Papulopustular Rosacea
Currently open trials in the same condition.
- NCT06952517 — Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea · Phase 2 · recruiting
Other Sol-Gel Technologies, Ltd. trials
Trials by the same sponsor.
- NCT04308395 — Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) · Phase 3 · terminated
- NCT04155190 — An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcino · Phase 2 · terminated
- NCT04059523 — MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 · Phase 1 · completed
- NCT03703310 — Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas · Phase 3 · completed
- NCT03727074 — Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05675501 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sol-Gel Technologies, Ltd.
- Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing